There will be a price to pay for making vaccines too expensive
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Friday
February 03, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
FRIDAY, FEBRUARY 03, 2023
There will be a price to pay for making vaccines too expensive

Panorama

Mihir Sharma /Columnist
25 November, 2020, 03:05 pm
Last modified: 25 November, 2020, 04:35 pm

Related News

  • Hong Kong says 'hello' to woo back visitors after Covid
  • US to end Covid-19 emergency declarations on 11 May
  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Covid remains a public health emergency, says WHO
  • Holiday trips within China surge after lifting of Covid curbs

There will be a price to pay for making vaccines too expensive

Rather than fall further behind, poor countries could upend the current system of intellectual property rights

Mihir Sharma /Columnist
25 November, 2020, 03:05 pm
Last modified: 25 November, 2020, 04:35 pm
Moderna’s vaccine requires supercooled infrastructure. Photo: Bloomberg
Moderna’s vaccine requires supercooled infrastructure. Photo: Bloomberg

The world is unequal enough and the Covid-19 pandemic threatens to make things more unequal still. Poorer countries have had to take on debt they will struggle to pay back. Their more fragile healthcare systems and crowded cities forced them into stricter and more economically harmful lockdowns, and poverty rates have risen dramatically. Now, they rightly fear a staggered recovery from the pandemic will further disadvantage them, given how expensive vaccine rollouts look to be.

It should not be surprising then that several developing countries, led by India and South Africa, argued last week at the World Trade Organization's intellectual property rights council that IPR-related payments should be suspended for the duration of the pandemic for Covid-19 related vaccines, therapeutics and equipment. They worry about "intellectual property rights hindering or potentially hindering timely provisioning of affordable medical products" to their citizens.

The full council will meet on the subject in December. Whatever the outcome, the bid is a shot across the bow of the current IPR system. The issue isn't just about getting poor countries access to vaccines. It is about allowing them to choose the vaccine that best suits their populations and infrastructure, and ensuring that they get enough doses quickly enough that they don't have to wait until 2024 to resume normal life while the West and China move forward.

At one level, the current petition clearly amounts to overkill. There's no reason for all pandemic-related IPR to be suspended. Few developing countries will be interested, for example, in the vaccine produced by Moderna Inc., which requires the sort of super-cooled storage facilities they would struggle to build.

Most had already bet big on the vaccine from AstraZeneca Plc and the University of Oxford, which the company has promised to sell at cost to many developing countries. With news this weekend that the vaccine was, on average, 70% effective against preventing Covid-19, any argument that a wholesale suspension of property rights is needed to prevent poor-country taxes flowing into Big Pharma's coffers begins to sound quite thin.

Yet the fact remains that if those capital flows are forced to materialize — if not for vaccines, then as royalties for therapeutic treatments or cutting-edge tests — then developing countries can and will revolt. We need to ensure poorer countries aren't pushed to their limits if we want to avoid a breakdown in the global acknowledgement of IPR that would set back innovation worldwide.

This is the first test of importance that the global intellectual property system has faced — and it will not be the last. A future in which owners of algorithms, capital, data or platforms in the West exact unending rents from consumers and governments in poorer countries is far less likely than a wholesale repudiation of their right to do so by the rest of the world. An intellectual property regime that is not flexible enough to manage this crisis is one that will break under the weight of that techno-dystopia.

In other words, it is in everyone's interest — including the residents of the world's poorest countries, who depend upon innovation in the world's richest nations to improve their lives — to head off this disgruntlement before it has a chance to gather political momentum. Some corporations recognize this. AstraZeneca, for example, has promised not to profit off the vaccine as long as Covid-19 is a pandemic (though how they will declare the pandemic is at an end remains mysterious).

Some rich-country leaders do as well. Boris Johnson hosted a global vaccine conference and the United Kingdom has so far committed $700 million to the shared vaccine fund, COVAX. French President Emmanuel Macron has helped set up the Access to Covid-19 Tools Accelerator, or ACT-A, which offers the best chance of distributing not just vaccines, but also diagnostic tests and therapeutic treatments.

Yet most rich-country governments have produced pandemic-response packages that are sharply nationalist and inward-looking in nature. ACT-A's $38 billion budget is less than 1% of the amount that the Western world has committed to its lavish stimulus packages. And still Macron's initiative is struggling for cash, having raised only $3 billion so far.

The biggest culprit has been the United States. Neither President Donald Trump nor Democrats in Congress have shown any interest in helping fund this effort, even though the country's hopes for future prosperity depend on a functional global IPR system. If President-elect Joe Biden wants to demonstrate that the US is once again a good-faith contributor to global efforts, he could start by promising that his administration will do what's needed to ensure that ACT-A is fully funded. If the US takes a back seat even under Biden, its hopes of recovering global respect and leadership will be truly finished.

Bloomberg Special / Coronavirus chronicle / Features / Top News

Vaccine / expensive / Coronavirus / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • International Monetary Fund logo : AP via UNB
    IMF sets time-bound reform agenda as it releases first tranche of loan
  • Shipped Bhola gas to cost higher, yet cheaper than spot LNG
    Shipped Bhola gas to cost higher, yet cheaper than spot LNG
  • January exports rise nearly 6% riding on high-value RMG items
    January exports rise nearly 6% riding on high-value RMG items

MOST VIEWED

  • While the Padma bridge in operation is changing the lives of millions in the south for the better, passenger rush to Shimulia ghat died down. Photo: Masum Billah
    How are the Shimulia ghat businesses faring after Padma bridge?
  • After so many investments going embarrassingly wrong, as was the case with Sam Bankman-Fried, perhaps tech investors’ preference for less experience will wane. Photo: Bloomberg
    Are you the next Steve Jobs? Good luck raising money in 2023
  • Infographic: TBS
    How to redirect inward remittances to formal channels
  • An elderly couple's lonely battle to save Dhaka's trees
    An elderly couple's lonely battle to save Dhaka's trees
  • Photo: Bloomberg
    How the 'madoffs of Manhattan' can unravel Gautam Adani's empire
  • Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
    'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

Related News

  • Hong Kong says 'hello' to woo back visitors after Covid
  • US to end Covid-19 emergency declarations on 11 May
  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Covid remains a public health emergency, says WHO
  • Holiday trips within China surge after lifting of Covid curbs

Features

Six Jeep Wranglers and a special XJ Jeep Cherokee set out into the depths of Lalakhal, Sylhet for an experience of a lifetime. Photo: Ahbaar Mohammad

Jeep Life Bangladesh: A club for Jeep owners to harness the power of their vehicles

19h | Wheels
While the Padma bridge in operation is changing the lives of millions in the south for the better, passenger rush to Shimulia ghat died down. Photo: Masum Billah

How are the Shimulia ghat businesses faring after Padma bridge?

21h | Panorama
After so many investments going embarrassingly wrong, as was the case with Sam Bankman-Fried, perhaps tech investors’ preference for less experience will wane. Photo: Bloomberg

Are you the next Steve Jobs? Good luck raising money in 2023

21h | Panorama
An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

1d | Panorama

More Videos from TBS

A proper price formula can help investors to plan big

A proper price formula can help investors to plan big

10h | TBS Round Table
Rumors about Sarika that everyone thinks are true

Rumors about Sarika that everyone thinks are true

9h | TBS Entertainment
Mugging rife in Tejgaon, murder in Wari

Mugging rife in Tejgaon, murder in Wari

11h | TBS Current Affairs
What secrets are hidden behind Adani's wealth?

What secrets are hidden behind Adani's wealth?

10h | TBS Stories

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Photo: Collected
Energy

8 Ctg power plants out of production

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]